PRIVIA HEALTH GROUP INC (PRVA) Fundamental Analysis & Valuation
NASDAQ:PRVA • US74276R1023
Current stock price
23.12 USD
+0.11 (+0.48%)
At close:
23.12 USD
0 (0%)
After Hours:
This PRVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. PRVA Profitability Analysis
1.1 Basic Checks
- PRVA had positive earnings in the past year.
- PRVA had a positive operating cash flow in the past year.
- In multiple years PRVA reported negative net income over the last 5 years.
- In the past 5 years PRVA always reported a positive cash flow from operatings.
1.2 Ratios
- PRVA has a Return On Assets (1.67%) which is in line with its industry peers.
- PRVA's Return On Equity of 3.11% is in line compared to the rest of the industry. PRVA outperforms 58.00% of its industry peers.
- PRVA has a Return On Invested Capital (2.75%) which is comparable to the rest of the industry.
- Measured over the past 3 years, the Average Return On Invested Capital for PRVA is significantly below the industry average of 8.51%.
- The last Return On Invested Capital (2.75%) for PRVA is above the 3 year average (2.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.67% | ||
| ROE | 3.11% | ||
| ROIC | 2.75% |
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
1.3 Margins
- With a Profit Margin value of 1.08%, PRVA perfoms like the industry average, outperforming 57.00% of the companies in the same industry.
- PRVA's Profit Margin has declined in the last couple of years.
- PRVA has a Operating Margin (1.61%) which is comparable to the rest of the industry.
- In the last couple of years the Operating Margin of PRVA has declined.
- The Gross Margin of PRVA (9.87%) is worse than 74.00% of its industry peers.
- PRVA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.61% | ||
| PM (TTM) | 1.08% | ||
| GM | 9.87% |
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
2. PRVA Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
- Compared to 1 year ago, PRVA has more shares outstanding
- Compared to 5 years ago, PRVA has more shares outstanding
- There is no outstanding debt for PRVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- PRVA has an Altman-Z score of 4.52. This indicates that PRVA is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 4.52, PRVA belongs to the top of the industry, outperforming 83.00% of the companies in the same industry.
- PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.52 |
ROIC/WACC0.31
WACC8.94%
2.3 Liquidity
- PRVA has a Current Ratio of 1.60. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
- PRVA has a Current ratio of 1.60. This is in the better half of the industry: PRVA outperforms 64.00% of its industry peers.
- PRVA has a Quick Ratio of 1.60. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
- The Quick ratio of PRVA (1.60) is better than 65.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 |
3. PRVA Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 54.55% over the past year.
- Measured over the past years, PRVA shows a decrease in Earnings Per Share. The EPS has been decreasing by -9.93% on average per year.
- PRVA shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.26%.
- Measured over the past years, PRVA shows a very strong growth in Revenue. The Revenue has been growing by 21.04% on average per year.
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
3.2 Future
- The Earnings Per Share is expected to grow by 57.08% on average over the next years. This is a very strong growth
- Based on estimates for the next years, PRVA will show a quite strong growth in Revenue. The Revenue will grow by 10.44% on average per year.
EPS Next Y109.45%
EPS Next 2Y64.03%
EPS Next 3Y57.08%
EPS Next 5YN/A
Revenue Next Year13.79%
Revenue Next 2Y12.12%
Revenue Next 3Y11.91%
Revenue Next 5Y10.44%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. PRVA Valuation Analysis
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 136.00, the valuation of PRVA can be described as expensive.
- The rest of the industry has a similar Price/Earnings ratio as PRVA.
- PRVA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.34.
- With a Price/Forward Earnings ratio of 64.93, PRVA can be considered very expensive at the moment.
- PRVA's Price/Forward Earnings ratio is in line with the industry average.
- PRVA's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 38.18.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136 | ||
| Fwd PE | 64.93 |
4.2 Price Multiples
- 62.00% of the companies in the same industry are cheaper than PRVA, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, PRVA is valued a bit cheaper than 66.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.77 | ||
| EV/EBITDA | 54.62 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- PRVA's earnings are expected to grow with 57.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.24
PEG (5Y)N/A
EPS Next 2Y64.03%
EPS Next 3Y57.08%
5. PRVA Dividend Analysis
5.1 Amount
- PRVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PRVA Fundamentals: All Metrics, Ratios and Statistics
23.12
+0.11 (+0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-26 2026-02-26/bmo
Earnings (Next)05-07 2026-05-07/bmo
Inst Owners99.13%
Inst Owner Change0.03%
Ins Owners1.81%
Ins Owner Change5.08%
Market Cap2.90B
Revenue(TTM)2.12B
Net Income(TTM)22.92M
Analysts84.29
Price Target33.06 (42.99%)
Short Float %2.11%
Short Ratio2.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.55%
Min EPS beat(2)-8.97%
Max EPS beat(2)96.08%
EPS beat(4)1
Avg EPS beat(4)-2.92%
Min EPS beat(4)-60.96%
Max EPS beat(4)96.08%
EPS beat(8)1
Avg EPS beat(8)-23.29%
EPS beat(12)3
Avg EPS beat(12)-1.19%
EPS beat(16)6
Avg EPS beat(16)61.33%
Revenue beat(2)1
Avg Revenue beat(2)5.86%
Min Revenue beat(2)-6.18%
Max Revenue beat(2)17.91%
Revenue beat(4)3
Avg Revenue beat(4)4.55%
Min Revenue beat(4)-6.18%
Max Revenue beat(4)17.91%
Revenue beat(8)7
Avg Revenue beat(8)4.33%
Revenue beat(12)10
Avg Revenue beat(12)3.07%
Revenue beat(16)10
Avg Revenue beat(16)-7.25%
PT rev (1m)2.82%
PT rev (3m)2.73%
EPS NQ rev (1m)-3.01%
EPS NQ rev (3m)10.44%
EPS NY rev (1m)1.65%
EPS NY rev (3m)11.12%
Revenue NQ rev (1m)0.09%
Revenue NQ rev (3m)-31.3%
Revenue NY rev (1m)-2.21%
Revenue NY rev (3m)-37.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 136 | ||
| Fwd PE | 64.93 | ||
| P/S | 1.37 | ||
| P/FCF | 17.77 | ||
| P/OCF | 17.77 | ||
| P/B | 3.94 | ||
| P/tB | 9.33 | ||
| EV/EBITDA | 54.62 |
EPS(TTM)0.17
EY0.74%
EPS(NY)0.36
Fwd EY1.54%
FCF(TTM)1.3
FCFY5.63%
OCF(TTM)1.3
OCFY5.63%
SpS16.9
BVpS5.87
TBVpS2.48
PEG (NY)1.24
PEG (5Y)N/A
Graham Number4.74
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.67% | ||
| ROE | 3.11% | ||
| ROCE | 4.27% | ||
| ROIC | 2.75% | ||
| ROICexc | 6.87% | ||
| ROICexgc | N/A | ||
| OM | 1.61% | ||
| PM (TTM) | 1.08% | ||
| GM | 9.87% | ||
| FCFM | 7.7% |
ROA(3y)1.75%
ROA(5y)-4.65%
ROE(3y)3.16%
ROE(5y)-7.26%
ROIC(3y)2.17%
ROIC(5y)N/A
ROICexc(3y)6.14%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.37%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-16.37%
OM growth 3YN/A
OM growth 5Y-12.3%
PM growth 3YN/A
PM growth 5Y-22.33%
GM growth 3Y-0.24%
GM growth 5Y-0.49%
F-Score6
Asset Turnover1.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 136.39 | ||
| Cash Conversion | 370.18% | ||
| Profit Quality | 712.96% | ||
| Current Ratio | 1.6 | ||
| Quick Ratio | 1.6 | ||
| Altman-Z | 4.52 |
F-Score6
WACC8.94%
ROIC/WACC0.31
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)607.4%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.55%
EPS 3Y9.35%
EPS 5Y-9.93%
EPS Q2Q%133.33%
EPS Next Y109.45%
EPS Next 2Y64.03%
EPS Next 3Y57.08%
EPS Next 5YN/A
Revenue 1Y (TTM)22.26%
Revenue growth 3Y16.09%
Revenue growth 5Y21.04%
Sales Q2Q%-31.71%
Revenue Next Year13.79%
Revenue Next 2Y12.12%
Revenue Next 3Y11.91%
Revenue Next 5Y10.44%
EBIT growth 1Y101.6%
EBIT growth 3YN/A
EBIT growth 5Y6.15%
EBIT Next Year475.2%
EBIT Next 3Y99.86%
EBIT Next 5Y56.77%
FCF growth 1Y49.53%
FCF growth 3Y51.38%
FCF growth 5Y33.52%
OCF growth 1Y49.53%
OCF growth 3Y51.28%
OCF growth 5Y33.26%
PRIVIA HEALTH GROUP INC / PRVA Fundamental Analysis FAQ
What is the fundamental rating for PRVA stock?
ChartMill assigns a fundamental rating of 5 / 10 to PRVA.
Can you provide the valuation status for PRIVIA HEALTH GROUP INC?
ChartMill assigns a valuation rating of 3 / 10 to PRIVIA HEALTH GROUP INC (PRVA). This can be considered as Overvalued.
What is the profitability of PRVA stock?
PRIVIA HEALTH GROUP INC (PRVA) has a profitability rating of 4 / 10.
What is the earnings growth outlook for PRIVIA HEALTH GROUP INC?
The Earnings per Share (EPS) of PRIVIA HEALTH GROUP INC (PRVA) is expected to grow by 109.45% in the next year.